Back to results
US 8,541,456 B2Granted
Roflumilast for the treatment of diabetes mellitus type 2
AssigneeTakeda GmbH
InventorsHans-Peter Kley, Guido Hanauer, Daniela Hauser, Beate Schmidt, Dirk Bredenbröker, Wilhelm Wurst, Jörg Kemkowski
Life of this patent
Estimating the term…
Abstract
The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.
Claims8
A pharmaceutical composition comprising a pharmaceutical formulation including a first amount of a compound of formula 1.1
- or a pharmaceutically acceptable salt thereof and/or a compound of formula 1.2
- or a pharmaceutically acceptable salt thereof, a second amount of a PPAR-agonist selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, RAGAGLITAZAR, FARGLITAZAR, TESAGLITAZAR, NAVEGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, FK-614, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2, and at least one pharmaceutically acceptable auxiliary.
A method for treating diabetes mellitus type 2 comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical formulation including a first amount of a compound of formula 1.1
- or a pharmaceutically acceptable salt thereof and/or a compound of formula 1.2
- or a pharmaceutically acceptable salt thereof, a second amount of a PPAR-agonist selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, RAGAGLITAZAR, FARGLITAZAR, TESAGLITAZAR, NAVEGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, FK-614, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2, and at least one pharmaceutically acceptable auxiliary.
Dependencies are inferred from the claim text.